

1 *A European Community COST ACTION grant proposal*

2
3 **MARISTEM - STEM CELLS OF MARINE/AQUATIC INVERTEBRATES: FROM**
4 **BASIC RESEARCH TO INNOVATIVE APPLICATIONS**

5
6 **Loriano Ballarin^{1*}, Baruch Rinkevich², Kerstin Bartscherer³, Artur Burzynski⁴, Sebastien Cambier⁵,**
7 **Matteo Cammarata⁶, Isabelle Domart-Coulon⁷, Damjana Drobne⁸, Juanma Encinas⁹, Uri Frank¹⁰,**
8 **Anne-Marie Genevriere¹¹, Bert Hobmayer¹², Helike Löhelaid¹³, Daniel Lyons¹⁴, Pedro Martinez¹⁵,**
9 **Paola Oliveri¹⁶, Lorena Peric¹⁷, Stefano Piraino¹⁸, Andreja Ramsak¹⁹, Sebastian Rakers²⁰, Fabian**
10 **Rentzsch²¹, Amalia Rosner²², Tiago Henriques da Silva²³, Ildiko Somorjai²⁴, Sherif Suleiman²⁵ and**
11 **Ana Varela Coelho²⁶**

12 ¹ Dipartimento di Biologia, University of Padova, Via U. Bassi 58/B 35100 Padova - Italy;

13 loriano.ballarin@unipd.it

14 ² Israel Oceanography and Limnological Research, National Institute of Oceanography, Tel Shikmona, PO
15 Box 8030, Haifa 31080, Israel; buki@ocean.org.il

16 ³ Max Planck Institute for Molecular Biomedicine, Röntgenstraße 20, and Medical Faculty, University of
17 Münster, Albert-Schweitzer-Campus 1, 48149 Münster, Germany;

18 kerstin.bartscherer@mpi-muenster.mpg.de

19 ⁴ Institute of Oceanology, Polish Academy of Sciences, Powstańców Warszawy 55, 81-712, Sopot, Poland;

20 aburzynski@iopan.gda.pl

21 ⁵ Luxembourg Institute of Science and Technology, 5, avenue des Hauts-Fourneaux, L-4362 Esch-sur-Alzette,
22 Luxembourg; sebastien.cambier@list.lu

23 ⁶ Department of Earth and Marine Sciences, University of Palermo, Via Archirafi 22, 90123 Palermo, Italy;

24 matteo.cammarata@unipa.it

25 ⁷ Muséum National d'Histoire Naturelle, MCAM Laboratory (UMR 7245CNRS-MNHN) 75005 Paris, France;

26 icoulon@mnhn.fr

27 ⁸ Biotechnical Faculty, University of Ljubljana, Večna pot 111, 1000 Ljubljana, Slovenia;

28 damjana.drobne@bf.uni-lj.si

29 ⁹ Achucarro Basque Center for Neuroscience, Science Park of the UPV/EHU, Sede Building, Barrio Sarriena,
30 E-48940 Leioa, and Ikerbasque, The Basque Foundation for Science. María Díaz Haroko Kalea, 3, 48013

31 Bilbao, Spain; jm.encinas@ikerbasque.org

32 ¹⁰ School of Natural Sciences, Biomedical Science Building, Dangan, National University of Ireland, Galway,
33 Ireland; uri.frank@nuigalway.ie

34 ¹¹ Sorbonne Université, UPMC, Univ Paris 06, CNRS, Biologie Intégrative des Organismes Marins (BIOM),
35 Observatoire Océanologique, F-66650 Banyuls/Mer, France; anne-marie.genevriere@obs-banyuls.fr

36 ¹² Institut für Zoologie, Universität Innsbruck, Technikerstraße 50, A-6020 Innsbruck, Austria;

37 Bert.Hobmayer@uibk.ac.at

38 ¹³ Tallinn University of Technology, Ehitajate tee 5, 19086 Tallinn, Estonia; helike.lohelaid@ttu.ee

39 ¹⁴ Center for Marine Research, Ruđer Bošković Institute, G. Paliaga 5, HR-52210 Rovinj, Croatia; lyons@irb.hr

40 ¹⁵ Departament de Genètica, Universitat de Barcelona, Av. Diagonal 643, 08028-Barcelona, Spain and Institut
41 Català de Recerca i Estudis Avancats (ICREA), Barcelona, Spain; pedro.martinez@ub.edu

42 ¹⁶ GEE & CDB Departments, University College London, Darwin Building, Gower Street, London, WC1E 6BT,
43 UK; p.oliveri@ucl.ac.uk

44 ¹⁷ Rudjer Boskovic Institute, Laboratory for Aquaculture and Pathology of Aquaculture Organisms, Bijenicka
45 cesta 54, HR-10000 Zagreb, Croatia; lorena.peric@cim.irb.hr

46 ¹⁸ Dipartimento di Scienze e Tecnologie Biologiche ed Ambientali, Università del Salento, Strada Provinciale
47 Lecce-Monteroni, 73100 Lecce, Italy; stefano.piraino@unisalento.it

48 ¹⁹ National Institute of Biology, Marine Biology Station, Fornače 41, SI-6330 Piran, Slovenia;

49 andreja.ramsak@nib.si

50 ²⁰ Fraunhofer Research Institution for Marine Biotechnology and Cell Technology, Mönkhofer Weg 239a,
51 23562 Lübeck, Germany; sebastian.rakers@emb.fraunhofer.de

52 ²¹ Sars International Centre for Marine Molecular Biology, University of Bergen, Thormøhlensgt. 55, N-5006
53 Bergen, Norway; Fabian.Rentzsch@uib.no

- 54 ²² Israel Oceanography and Limnological Research, National Institute of Oceanography, Tel Shikmona, PO
55 Box 8030, Haifa 31080, Israel; amalia@ocean.org.il
- 56 ²³ Biomaterials, Biodegradables and Biomimetics, University of Minho, AvePark - Parque de Ciência e
57 Tecnologia, 4805-017 Barco, Guimarães, Portugal; tiago.quinteiros@gmail.com
- 58 ²⁴ Scottish Oceans Institute, East Sands, University of St Andrews, KY16 8LB and School of Biology, Biomedical
59 Sciences Research Complex, North Haugh, University of St Andrews, St Andrews, KY16 9ST, UK;
60 imls@st-andrews.ac.uk
- 61 ²⁵ Anatomy Department, Faculty of Medicine & Surgery, University of Malta, Msida, MSD2080, Malta;
62 sherif.s.suleiman@um.edu.mt
- 63 ²⁶ Universidade Nova de Lisboa, ITQB NOVA, Instituto de Tecnologia Química e Biológica António Xavier,
64 Av. da República, 2780-157 Oeiras, Portugal; Varela@itqb.unl.pt
- 65
- 66 * Correspondence: loriano.ballarin@unipd.it; Tel.: +39 049 827 6197
- 67

68 **Abstract:** The “stem cells” discipline represents one of the most dynamic areas in biomedicine.
69 While adult marine/aquatic invertebrate stem cell (MISC) biology is of prime research and medical
70 interest, studies on stem cells from organisms outside the classical vertebrate (e.g., human, mouse,
71 zebrafish) and invertebrate (e.g., *Drosophila*, *Caenorhabditis*) models have not been pursued
72 vigorously. Marine/aquatic invertebrates constitute the largest biodiversity and the widest
73 phylogenetic radiation on Earth, from morphologically simple organisms (e.g. sponges, cnidarians),
74 to the more complex mollusks, crustaceans, echinoderms and protochordates. These organisms
75 illustrate a kaleidoscope of MISC-types that participate in the production of a large number of novel
76 bioactive-molecules, many of which are of significant potential interest for human health. MISCs
77 further participate in aging and regeneration phenomena, including whole-body regeneration.
78 For years, the European MISC-community has been highly fragmented and scarce ties were
79 established with biomedical industries in attempts to harness MISCs for human welfare. Thus, it is
80 important to: i) consolidate the fragmented European community working on MISCs; ii) promote
81 and coordinate European research on MISC biology; iii) stimulate young researchers to embark on
82 research in MISC-biology; iv) develop, validate, and network novel MISC tools and methodologies;
83 v) establish the MISC discipline as a forefront interest of biomedical disciplines, including
84 nanobiomedicine; vi) establish collaborations with industries to exploit MISCs as sources of
85 bioactive molecules. In order to fill the recognised gaps, the EC-COST Action 16203 “MARISTEM”,
86 has recently been launched. At its initial stage the consortium unites 26 scientists from EC countries,
87 Cooperating countries and Near Neighbor Countries.

88 **Keywords:** aging; bioactive molecules; blue biotechnology; cancer; cell culture; COST Action;
89 Europe; marine/aquatic invertebrates; regeneration; stem cells

92 1. Science and Technology Excellence of the Project

93 1.1 Challenge

94 1.1.1 Description of the Challenge (Main Aim)

95 The primary aim of this COST Action is to foster, at the European level, knowledge of the biology of
96 marine/aquatic invertebrate stem cells (MISCs) to develop innovative ideas relevant to various
97 environmental and biomedical disciplines. In line with the Ostend declaration [1] and the European
98 Marine Board strategic recommendations [2], specific aims of this Action are: (a) to overcome the
99 scientific boundaries and obstacles facing the European MISC community; (b) to consolidate the
100 fragmented community; (c) to integrate the MISC field with environmental (e.g. ecotoxicity and
101 impacts of environmental stressors) and biomedical disciplines (such as aging, cancer, immunology,
102 regeneration, stem cell biology, etc.); (d) to strengthen the European research community on MISCs.
103 This will be accomplished by promoting: i) joint research on stem cell biology; ii) the sharing
104 innovative ideas and discussion on compared models; iii) coordination of research in MISC biology;
105 iv) establishing ties with biomedical and biotechnology industries to harness MISCs for animal and
106 human welfare, as well as sources of molecules of interest for biotechnological purposes; v) training
107 the next generation of biologists in MISC research.

108 1.1.2 Relevance and Timeliness

109 Marine/aquatic invertebrates represent a large biodiversity assemblage of multicellular organisms
110 and the widest phylogenetic radiation on Earth, with more than 2,000,000 species formally described
111 (95% of the overall animal biodiversity). They have been employed as laboratory models for more
112 than 150 years and have contributed to the elucidation of various biological problems. Of particular
113 significance were the first experiments on phagocytosis in sea star larvae [3], the first studies on
114 biological chimeras in corals [4], the importance of the sea urchin to understand the molecular basis
115 of development [5-7], including the “gene regulatory networks”, the molecular control of
116 proliferation (cyclins identified there) [8], the studies on primitive immunity in colonial organisms
117 (sponges, hydrozoans, corals, urochordates, bryozoans), the plasticity of development, the use of
118 aquatic flatworms for regeneration studies [9] and the discovery of green fluorescent protein in
119 cnidarians [10], among many others.

120 While up until a few years ago, the use of invertebrates as model organisms was limited by the
121 paucity of “-omics” data, the situation has rapidly changed and is still changing. Today, the
122 genomes and various transcriptomes of many marine/aquatic invertebrate species (Non-Bilateria,
123 Ecdysozoa, Spiralia and Deuterostomata), as well as many recombinant proteins of invertebrate
124 origin, are available. New technologies such as RADseq, RNAseq, CHIP-sequencing and other
125 next-generation sequencing methods), epigenome characterization, mass spectrometry and protein
126 profiling, reverse-phased protein microarrays, combined with novel bioinformatic tools, have
127 revolutionized the available tool-box of research methodologies. These can be used to further
128 develop marine/aquatic invertebrates as reliable model organisms in a variety of biological research,
129 including their stem cells. There are three major routes of involvement where MISCs are highly
130 relevant and timely:

131 a) The understanding of fundamental biological processes. MISCs are key players in the biology of
132 aquatic invertebrates, with a central role in many biological processes [11-12]. While much is known
133 about adult stem cells and their properties in vertebrates (primarily mammals) and some model
134 terrestrial invertebrates (i.e., *Drosophila*), very little has been learnt on the nature and properties of
135 MISCs. Aquatic invertebrates exhibit multiple cell types with stem cell attributes. Studies revealed
136 that, in contrast to the prevalence of diverse oligopotent and unipotent stem cells in vertebrates,
137 marine invertebrates appear to display the communal spread of multipotency and pluripotency [10],
138 with adult stem cells that give rise to cell lineages characteristic of more than a single germ layer,
139 sometimes with somatic and germ line potential. In addition, unlike vertebrates, in many

140 aquatic/marine invertebrates, stem cells are disseminated and widespread inside the animal body,
141 i.e., not associated with a regulatory microenvironment (niche) [12-13]. It is also of note that
142 transdifferentiation (today, a topic of great interest when trying to understand how to
143 “reprogramme” a cell) is prevalent in both anatomically simple and “morphologically complex”
144 invertebrates [14-15]. These observations delineate common and unique properties of MISCs,
145 possibly tailored to suit the varied life history traits, ecology and developmental modes
146 characteristic of aquatic invertebrates [10].

147 b) Alternatives to the use of vertebrates. The recent directive of the EU (2010/63/EU) [16] on the
148 protection of animals used for scientific purposes is highly restrictive for the use of complex,
149 classical vertebrate models in biological research. Following the general scientific trend and to
150 bypass restrictions imposed by the directive on behalf of the protection of animals, researchers
151 turned to the use vertebrate cell lines and primary cultures to provide answers to a wide array of
152 biological questions. This approach greatly limits the comprehension of biological phenomena at the
153 organismal level as well as from an evolutionary perspective. Unlike vertebrates, invertebrates
154 (cephalopods excluded) are not included in the EU directive and offer the possibility of *in vivo*
155 analyses. In many cases, they not only successfully replace mammals or other vertebrates as
156 laboratory animals in biological research but also provide added value due to their simpler body
157 organization or reduced genetic complexity, and by presenting biological phenomena that do not
158 occur in vertebrates (like whole body regeneration, concealed vs. programmed aging, etc.).

159 c) The importance of MISCs for the biomedical and biotechnology industries. Marine/aquatic
160 biotechnology is an emerging discipline aiming at the use of marine bio-resources for
161 biotechnological applications (Blue Biotechnology) [2, 17-20]. However, industries traditionally lack
162 familiarity with the marine environment. The latter, with its vast genetic richness, is a potential
163 source of new products of socio-economic value, as marine organisms produce molecules (enzymes,
164 biopolymers, bioactive compounds, secondary metabolites) with applications in various fields, such
165 as nutraceuticals, cosmetics, antibiotics, disease-fighting drugs, antifouling products, biomaterials and
166 more [21-25]. In addition, marine invertebrates exhibit a kaleidoscope of MISC types that participate
167 in the production of this plethora of novel bioactive molecules (antitumor, antimicrobial, and
168 anti-inflammatory), with significant potential interest for human health and well being. MISCs also
169 participate in unique aging and regeneration phenomena, including whole-body regeneration,
170 implying lack of senescence/aging [9, 26], and are responsible of the presence of unique stemness
171 systems, without the formation of tumors, the knowledge of which could be of great help in
172 medicine. The increasing availability of genomes from marine animals will allow the rapid detection
173 of the gene networks involved in these biological phenomena, as well as biosynthetic pathways of
174 new useful bioactive molecules and metabolites through the functional analysis of cloned gene
175 libraries. In addition, marine organisms and their cells are of great use to study the impacts of
176 environmental stressors, global warming and ocean acidification on biota.

177 **The European MISC community, however, confronts these scientific boundaries and obstacles:**

178 a) Ties with biomedical and biotechnology industries. Current European marine/aquatic
179 biotechnology initiatives are mainly focused on identifying novel molecules and biosynthetic
180 pathways, but there is a critical lack of cellular models able to express biomolecules and test their
181 effect on environmentally significant organisms. At present, most of the research on MISCs is
182 primarily fundamental, leading to papers published in scientific journals; but precisely this may
183 stand in the way of commercialization and economic criteria. All this knowledge needs to be
184 translated into innovation. The future of marine biotechnology (including MISC research) for
185 industrial and medical applications is very promising. The global market for marine biotechnology
186 is estimated at 4.1 billion USD in 2015, and has the potential to reach 4.8 billion USD by 2020 and 6.4
187 billion USD by 2025 [27]. The marine environment accounts for the great majority of the ecosystems
188 and living species on Earth. Marine biotechnology follows the diverse opportunities that have
189 emerged in a wide variety of biotechnology areas and medical fields, from basic research to
190 industrial applications. In the European Community, interest in marine biotechnology by the
191 scientific community, and to some extent by the industry, has grown rapidly in the past decade. The

192 main drivers are the recognition of the sheer scale of opportunity presented by the largely
193 unexplored and immense biodiversity of European seas and oceans and the increasing availability of
194 molecular tools to explore this biodiversity. However, cellular tools are critically lacking to validate
195 these molecular studies. Such important barriers and challenges need to be tackled at various levels
196 for Europe to remain a key player in marine biotechnology research [2]. Part of the problem is the
197 relatively low spending of gross domestic product on research and development in the marine arena.
198 Another obstacle is that the EU, it takes too long to transform research and innovation results into
199 marketable products.

200 b) Social implications. Boosting marine innovation through biotechnology-related activities is
201 specifically highlighted in Horizon 2020: under the priority 'Better Society' [28]. This is widely
202 supported by the notion that the successful development of the marine biotechnology sector in
203 Europe would be performed within an industry-academic collaborative environment. However,
204 recent developments in green biotechnology, nanotechnology and synthetic biology have shown
205 how critical the social acceptability of new technological knowledge has become. Social acceptance
206 of the MISC technology, and marine biotechnology as a whole, faces an important challenge in
207 convincing a large array of stakeholders that, on one hand, it does not build on irresponsible
208 knowledge, and, on the other hand, it can fulfill the numerous promises made [29]. This COST
209 Action will help to identify the main bottlenecks that could impede the development of the MISC
210 discipline and, therefore, provide standards and guidance in dealing with the corresponding policy
211 issues, with input into the recent European move towards Responsible Research and Innovation
212 initiative.

213 c) Need for coordinated European research on marine/aquatic stem cells. The community engaged in
214 MISC in COST countries is highly fragmented, each laboratory working on its organism or cell of
215 choice using different methodologies. A preliminary census in COST countries led to the
216 identification of >200 MISC scientists in different institutions, located in coastal and in inland
217 laboratories, employed by the government, universities and research institutions. Additionally,
218 numerous scientists are employed by biotechnology entities. In other marine sciences fields (e.g.,
219 oceanography), the need for sharing costly research instruments (e.g., vessels) has led to higher
220 research integration. Since this is not the case for MISC research in COST countries, far fewer
221 scientific innovations have been produced, negatively affecting this discipline.

222 d) Training of next generation researchers. Unlike the ongoing European Blue Biotech projects,
223 focused on molecules and genes of biological interest, this COST Action is mainly biodiversity
224 oriented, with particular attention to stem cells and their potential for applied research. In general,
225 there is a lack of European students and young scientists with a thorough knowledge of the
226 marine/aquatic biodiversity who also receive the practical training in cutting-edge techniques and
227 cellular approaches that underpin ongoing developments in marine biotechnology, including MISC.
228 There is also a clear need to support high quality new students and young researchers with a broad
229 education in marine science, medicine and biotechnology that are ready to become leaders in this
230 rapidly expanding field. Additionally, there is a shortage of university programmes which focus on
231 the sea in integrated courses, research and practical experience, as well as few partnerships of the
232 universities with the local biotechnology industry. It is therefore a prime mission to prepare a new
233 generation of talented students for careers in the MISC discipline (research and industry). This field
234 will not be developed without a constant flow of young scientists actively involved in the various
235 aspects of MISC research. Up to now, only a small number of graduate students have engaged with
236 MISCs, primarily due to the lack of established and standardized methodologies. Addressing
237 specific needs in education and training in the field of marine biotechnology (including MISCs), will
238 bring together crosscutting disciplines such as marine biology, cell biology, bio-informatics, systems
239 biology, synthetic biology, etc.

240

241 1.2 Objectives

242 1.2.1 Research Coordination Objectives

243 *MARISTEM* has a pan- European focus on stem cells from marine (as well as aquatic) invertebrates
244 (MISCs) and connects to the EC- International Partner Countries (IPCs), EC-Associated Countries
245 (AC) and Near Neighbor Countries (NNCs) to achieve its Research Coordination Objectives. The
246 following objectives aim to overcome the fragmentation within the European MISC community,
247 strengthen the collaboration among the European research community on MISCs, foster the MISC
248 discipline at the academic level, and link the MISC research area with biomedical disciplines (such as
249 aging, cancer, immunology, regeneration, stem cell biology, etc.). Research coordination activities
250 include:

- 251 1. Consolidation of the European community of scientists involved in MISC research. This will be
252 accomplished through the: i) organization of annual meetings for data sharing; ii) promotion of
253 Short-Term Scientific Missions for technical training; iii) creation of an Action website and a
254 newsletter acting as a discussion forum for MISC issues central to the MISC community; iv) setting
255 up new collaborations among participants; v) organization of workshops on MISC and specific
256 methodologies related to MISCs, in particular addressing the bottlenecks in MISC identification and
257 *in vitro* culture; vi) publication of an updated review on MISCs in a qualified scientific journal; vii)
258 organization of participants in Working Groups to address the scientific tasks described below.
- 259 2. Presentation of MISC research, sharing of methodologies/databases used in MISC research in
260 various European countries, and updating scientific and technical guidelines for standardization of
261 methods, techniques and protocols, to maximize the extent and the quality of the results. The
262 objectives should be achieved through an integrated effort to develop technologies that allow the
263 isolation, phenotyping and culture of stem cells, and those state-of-the art methodologies that allow
264 us to test the effectiveness of MISC-derived bioactive molecules in biomedicine and biotechnology.
- 265 3. Establish ties with biomedical and biotechnology industries for the exploitation of MISCs and the
266 derived results (for instance, in the fields of immunity, regeneration and aging, bioactive molecules).
- 267 4. Coordinate funding applications, at European level, emphasizing doctoral and post-doctoral
268 research opportunities.
- 269 5. Coordinate collaborative and scientific ties, at the international level, with scientists working on
270 MISCs, primarily from the USA and Japan.

271 1.2.2. Capacity- Building Objectives

272 *MARISTEM* seeks to drive both scientific progress and technological innovation in the MISC field of
273 research through the following four major Capacity Building Objectives:

- 274 1. Strengthening the European Community on MISC through the setting up of new collaborations
275 among participants and the promotion of Short-Term Scientific Missions for technical training.
- 276 2. Promoting interactions of Action members to establish a defined identity and profile in the
277 European field of MISC; establishing ties with European networks, scientific societies/institutions
278 and/or large-scale funded projects in related fields (e.g., European Society for Marine Biotechnology,
279 Assemble Plus, EuroMarine, EuroStemCell, EMBRC-ERIC, Corbel, EuroSyStem, Neurostemcell,
280 Neurostemcellrepair, OptiStem, ESTOOLS).
- 281 3. Stimulating contacts and the development of a joint research agenda in order to strengthen future
282 research on MISCs.
- 283 4. Establishing working groups, as listed below, to collaborate on specific topics with defined tasks.

284

285 1.3 Progress beyond the State-of-the Art and Innovation Potential

286 1.3.1 Description of the State-of-the Art

287 Stem cells in multicellular organisms possess the unique ability to remain in undifferentiated state
288 and, upon demand, originate cells that differentiate. This has been well established in vertebrates
289 and terrestrial invertebrates, where much of the research activities have been linked to applied
290 aspects of stem cell biology. However, the excessive focus on the applied outcomes of stem cell
291 biology poses the risk of missing the wide range of stem cell properties that are represented in
292 various multicellular taxa, primarily in taxa belonging to the aquatic invertebrates. In addition,
293 working on vertebrate systems is extremely expensive and raise several ethical concerns. In many
294 activities, invertebrates can replace vertebrates and, in addition, they can offer new perspectives on
295 MISC function, properties and evolution.

296 Not only do MISCs share a whole range of novel biological properties but, unlike vertebrates, they
297 are also key participants in aging and regeneration phenomena. The comparison of well-known
298 biological processes in model systems with novel phenomena, associated with the biology of MISCs,
299 can help to better understand events in mammalian stem cells biology - including natural chimerism
300 and cancer, aging and senescence, immunity and autoimmune responses - all representing
301 phenomena difficult to directly address within the human context.

302 A careful literature search attests to the fact that studies on stem cells from organisms that not
303 defined as the classical model systems (such as human, mouse, zebrafish, *Drosophila*, *Caenorhabditis*,
304 etc.), have not been pursued vigorously. This is because these cells are generally few in number,
305 sometimes not specifically characterized, are studied in biological systems not amenable for *in vitro*
306 work and, probably, are less plastic.

307 Recent studies have shown that the best organisms for stem cell research are the marine/aquatic
308 invertebrates. These organisms possess numerous types and lineages of stem cells that can offer,
309 once studied in the lab, important clues to the understanding of stem cell biology. Stem cells are
310 present in marine/aquatic organisms, in either (morphologically) simple organisms, such as
311 cnidarians, sponges and flatworms, or in anatomically more complex taxa, such as crustaceans,
312 echinoderms and protochordates (urochordates and cephalochordates) (Fig. 1). Unique to many of
313 the aforementioned marine invertebrates, is the property that some adult MISCs are pluripotent,
314 capable of developing both the germ line and somatic tissues, and are involved in asexual
315 reproduction and regeneration. Marine organisms challenge the prevailing dogmas on stem cell
316 structures, niches and cell lineages biology. They also challenge the existing concepts on the genetic
317 and epigenetic control of stem cell differentiation. Due to their simpler morphological and tissue
318 organization and the accessibility of some of them to genetic manipulation, marine/aquatic
319 invertebrates are reliable and efficient model systems to investigate the molecular basis of stemness
320 and stem cell regulation. This problematics can be accomplished by analyzing the molecular
321 interactions between stem cells and their niches, under controlled *in vivo* conditions.

322



323

324 **Figure 1.** Colony of the ascidian *Botryllus schlosseri*. In this species, zooids are grouped in star-shaped
 325 systems (two systems are visible here) and stem cells assure the rejuvenation of the colony through
 326 the cyclical production of pallear buds, as well as the whole body regeneration (also known as
 327 vascular budding), when all the zooids and buds are ablated and new zooids originated from the
 328 hemocytes in the tunic vasculature. **A:** ampulla (blind, contractile ending of the tunic circulation); **B:**
 329 bud; **CS:** cloacal siphon of the system; **OS:** oral siphon of the zooids; **T:** tunic; **V:** tunic vessel; **Z:**
 330 zooid. Scale bar: 1 mm.

331

332 1.3.2 Progress beyond the State-of-the Art

333 Many of the features revealed in MISCs have not been recorded in stem cells from vertebrates,
 334 including the almost absence of association with regulatory microenvironments (niches), their
 335 widespread distribution (and high percentage) in all marine animals, their pluripotency, and the
 336 feeble distinction between somatic and germ stem cells lineages, among others [30]. However, while
 337 the literature on stem cells from vertebrates is rich and expanding at an exponential rate,
 338 investigations on MISCs are scarce and limited in scope, despite the results underscoring the
 339 importance of MISCs in the understanding of various biological processes, such as the mechanisms
 340 promoting cell growth and differentiation, regeneration and budding typical of marine invertebrates,
 341 tissue homeostasis of marine organisms (including those that may live for decades), aging and
 342 senescence.

343 The concepts of stem cell-based organogenesis, aging, cancer and regeneration are interrelated and
 344 shared among evolutionary lineages. Therefore, stem cells are not only entities of biological
 345 organization, accountable for the formation and regeneration of specific tissue and organ systems,
 346 but are also units in the complex evolutionary selection process [31]. Thus, a clear understanding of
 347 the relationships between stem cells and the aforementioned processes, and the possibility of their
 348 conservation across systems will push the MISC community in Europe far ahead of the current
 349 state-of-the-art.

350 This COST Action, which proposes to strengthen the European research community on MISCs and
 351 promotes joint research among Action members on comparative stem cell biology, developing
 352 innovative ideas and technology, is the most appropriate tool for significant European progression,
 353 breaking through the current state-of-the-art. Exponential growth in the number of investigations on
 354 MISCs, as well as a more integrated European scientific community engaged with MISC research,

355 will offer exciting new avenues for advancing knowledge of MISC biology as well as providing
356 novel systems for medical and economical applications.

357 1.3.3 Innovation in Tackling the Challenge

358 Interdisciplinary approaches are crucial to tackle the challenges posed by MISC research and are
359 central to the proposed holistic, integrated approach to managing the MISC community. Pluripotent
360 MISCs provide powerful and physiologically-relevant systems to characterize the regulatory
361 mechanisms that control cellular differentiation at all organizational levels of biology, also
362 impacting on mammalian systems. We identify the following three key strategies to target current
363 and future scientific and economic awareness:

364 a) development of standardized and optimized protocols. Innovative technologies and strategies
365 that are currently and will continue to be employed and will be employed to decipher the
366 mechanisms that control the directed differentiation of pluripotent stem cells are the base rationale
367 for the scientific approach in tackling the challenge. There is the need to set up and share good
368 protocols for rearing marine invertebrates and for MISC isolation, culture and phenotyping. This
369 should be done on a wide spectrum of marine invertebrate species in order to support subsequent
370 comparative analyses. This approach requires the integration of different laboratories, in EC
371 countries and within universities/research institutions, and small biotech companies in each specific
372 EC state. The COST umbrella is probably the best and most innovative approach to tackle all the
373 challenges that have been presented here. Innovation will be achieved by addressing scientific
374 problems with clear objectives, such as those indicated in section 3 of this manuscript, and through
375 the frequent interactions among the Action members. This will also enhance competitiveness of the
376 EC research.

377 b) consolidation of the fragmented scientific arena. The scientific community in the European
378 countries currently engaged in MISC biology is fragmented and composed by too few established
379 scientists. The recruitment of a new generation of young scientists interested in MISCs, the
380 consolidation of the fragmented MISC community in Europe, the frequent meeting among members,
381 through participation in workshops, Action meetings and short term visits to other laboratories, will
382 favor the generation of new ideas and joint research projects in the field of MISC research.

383 c) Fostering contacts with industries. The MISC field needs to develop connections with relevant
384 biotechnology industries. One of the challenges faced is to convince the multiple types of
385 stakeholders (i.e., those reported in para 2.2.1) that, through its know-how and expertise, it can
386 achieve what is being promised. Contacts with industries interested in exploiting MISCs for their
387 regenerative potential and/or the production of bioactive molecules or metabolites useful in
388 animal/human welfare and/or biotechnological applications will be established. Marine/aquatic
389 organisms have revealed (and still can reveal) unexpected gene regulatory pathways of interest to
390 regenerative biology. In addition, they are known sources of valuable biologically active substances
391 for the pharmaceutical, biotechnology and food industries. Many marine secondary metabolites are
392 known for their highly effective antioxidant, antibacterial, antifungal, antifouling and antitumor
393 activities. Ideally, the possibility to produce such bioactive compounds using MISC-derived
394 immortalized cell lines would be of great importance in developing societal improvements and
395 advances. An academic-industrial collaborative approach can add new value to the applied MISC
396 research.

397 1.4. Added Value of Networking

398 1.4.1. In relation to the Challenge

399 Stem cell science is an emerging global industry in which European countries fiercely compete for
400 economic advantage in an arena where, currently, the USA and Japan dominate. Most European
401 groups (academics, as well as companies and SMEs [Small and Medium size Enterprises]) are
402 dispersing their scientific efforts using different biological models and methodologies, in an area

403 where no stream of knowledge and intellectual property are still available. There is thus a pressing
404 need for developing expertise, approaches and tools. The only way forward is by consolidating a
405 network of MISC groups sharing expertise. We cannot be competitive in the international arena if we
406 do not promote our own research groups/projects through collaborative, intra-EU actions.
407 Networking is one of the most efficient approaches for consolidation of the European MISC
408 community and for the raising of European competitiveness and leadership. Such networking
409 should focus on the biological diversity of MISCs and their structures, pluripotency properties,
410 development of understudied, unique or culturally valuable (e.g., aging, cancer) biological/applied
411 aspects. Thus, the Network will develop European leadership and expertise in the MISC discipline.
412 The fragmented research community currently limits European competitiveness also in technology
413 transfer to potential end-users. For example, there are currently few SMEs in COST countries that
414 consider MISCs as part of their R&D plan. Thus, our Action will not only offer a unique nucleus of
415 commercial importance, but also the pooling of individually acquired knowledge within a single
416 community, offering the participants better access to international grant agencies or products under
417 development in each country/group. Thus this COST Action will have a competitive ability to
418 develop innovative, effective, and flexible adaptation strategies that will address multiple national,
419 regional, and global priorities in key economic and social sectors.
420 Networking will promote the discussion of novelties and research results, will attract students to the
421 MISC discipline, will provide opportunities to mix newcomers with important players in the MISC
422 arena and stem cells biology discipline and learn about the potential offered by the markets. In
423 addition, amalgamating the EC community working on MISC (both academic and industries) may
424 pose significant challenges to the future of EC stem cell science. Particular attention will be paid to
425 the training of early-stage researchers by organizing summer schools, by favoring their mobility
426 through short-term scientific missions and by promoting their participation in scientific meetings
427 and workshops. We firmly believe that the coming generations of young researchers (trained in the
428 MISC discipline) will be the future leaders of marine science.

429 **1.4.2. In Relation to Existing Efforts at European and/or International Level**

430 Despite the great efforts and the variety of funding schemes and actions within Horizon 2020, no
431 former or existing scientific networks or projects in Europe dealt/are dealing with MISCs and, up to
432 now, no individual entity (either private or national institute) in the European MISC discipline has
433 gathered a critical mass of researchers and knowledge to become a globally leading contributor.
434 There is an urgent need to increase the cohesion between scientific institutions and industry in this
435 field via the creation of a COST network. This multidisciplinary collaboration would eventually
436 bypass methodological bottlenecks, gaps and barriers. Indeed, because of the fragmentation of the
437 scientific community, we do not know whether methodologies developed for other animal systems
438 are being utilized in developing MISC or have failed; likewise, failed experiments and approaches
439 are not being presented or published in peer-reviewed journals. This makes exchange of information
440 utterly crucial in the research community, sharing promising methods and avoiding replication of
441 failed or redundant procedures. De-fragmentation of the MISC scientific community is therefore
442 expected to revolutionize this field, resulting in novel and generic technologies and products.
443 This COST Action will be tightly connected with several European associations that deal with cell
444 cultures. One such important organization is the European Collection of Authenticated Cell Cultures
445 (ECACC), a supplier of authenticated and quality controlled cell lines [32]. ECACC was established
446 in 1985 as a cell culture collection to service the research community and to provide an International
447 Depository Authority for patent deposition for Europe. The same implies for the Horizon 2020
448 research and innovation program called EuroStemCell [33] that tries, among its major goals, 'to help
449 European citizens make sense of stem cells, by providing independent, expert-reviewed information
450 and road-tested educational resources on stem cells and their impact on society'. The MISC partners
451 will also team with the ECVAM [34], which is the EC reference Centre for the development and
452 validation of alternative testing methods to replace, reduce or refine the use of laboratory animals in
453 biomedical sciences, with an emphasis on toxicology assessment.

454 The proposed COST Action will be integrated within the Blue growth initiatives included in other
455 EU science consortia/networks/platforms (Assemble PLus, EuroMarine, EuroStemCells,
456 EMBRC-ERIC, Corbel, ERA-MBT, EuroSyStem, Neurostemcell, Neurostemcellrepair), and will
457 contact participants in current and former EU projects on marine and stem cell science, such as
458 MarBEF, EurOceans, MarineGenomics, OptiStem, ESTOOLS.

459 2. Impacts

460 2.1. Expected Impact

461 2.1.1. Short-term and Long-term Scientific, Technological, and/or Socioeconomic Impacts

462 The aim of this proposal is to mobilize the European scientific expertise in MISC research and
463 associated technological resources to provide professionals with relevant state-of-the-art
464 information, methods and tools for the amelioration and treatment of diseases (gene regulatory
465 networks, antimicrobials, antimitotic compounds), and for pharmaceutical and biotechnological
466 purposes (enzymes, polymers, secondary metabolites). The heavy investment in developing and
467 sharing technologies, from genomic/proteomic tools to those that use high throughput analysis of
468 chemical compounds, necessitates the support of a solid network of scientists with complementary
469 expertise. The MISC team will provide such a wide range of expertise. The Network will use the
470 following resources to determine how and when to involve end users in knowledge dissemination
471 plans. Knowledge translation (e.g. synthesis, dissemination, exchange, and ethically sound
472 application of knowledge) will be used to improve MISC activities within a system of interactions
473 between researchers and knowledge users. Interactions may vary in intensity, complexity, and level
474 of engagement depending on the research and findings, as well as the needs of particular knowledge
475 users.

476 Scientific-technological short-term impacts

- 477 • creation of a Europe-wide research network to answer key questions on MISCs;
- 478 • promotion of interactions among scientific institutions interested in MISCs;
- 479 • release of updated standardized scientific protocols/technical guidelines for rearing of
480 marine/aquatic invertebrates and MISC isolation and culture;
- 481 • creation of a registry/repository for sharing data on MISC research;
- 482 • creation of a website and a newsletter as a forum to link the MISC community;
- 483 • common publications in peer-reviewed and open access scientific journals describing optimized
484 protocols for MISC isolation and rearing.

485 Socio-economic short-term impacts:

- 486 • dissemination of COST Action results and public awareness on importance and potential of
487 MISCs;
- 488 • starting of collaboration with industries for the exploitation of MISCs;
- 489 • training of talented students/young researchers;
- 490 • stimulating the creation of new networks for fund-raising opportunities.

491 Scientific-technological long-term impacts:

- 492 • new insights on the biology of MISCs and on mechanisms controlling their *in vitro* growth and
493 evaluation of the possibility of the production of bioactive compounds from *in-vitro* culture of MISCs.
494 Results will represent a commonly distributed know-how;
- 495 • contribution to a wide range of biomedical disciplines, including regenerative medicine, aging and
496 cancer. The study of MISCs will increase commonly shared and evolutionary perspectives in these
497 disciplines, towards a more comprehensive understanding of these cells;
- 498 • positive impact on regeneration biology as marine/aquatic invertebrates have unique regeneration
499 potential and can contribute to the comprehension of the constraints preventing large scale
500 regeneration in vertebrates. MISCs can also be used to assay the impact of different chemicals in
501 their ability to regenerate tissues;

- 502 • new strategies for sustainable exploitation of marine/aquatic bioproducts, and for development of
503 alternative ecotoxicological tests, meeting international regulations, that can be used by biomedical
504 and biotechnological industries. The management of intellectual and industrial property rights
505 arising from this Action will ensure that eventual benefits of MISC project results are shared fairly
506 and reasonably among the institutions of the COST Action participants;
- 507 • better understanding the impact of environmental stressors (temperature, acidification, etc.) in
508 regeneration processes and the resilience of challenged aquatic ecosystems;
- 509 • MISCs can differentiate in a variety of cell lines, including hemocytes and, among them,
510 immunocytes. Therefore, the study of MISC differentiation to immunocytes can provide a better
511 elucidation of the behavior of the immune system in reared, edible marine/aquatic invertebrates and
512 help in the control of diseases and viral infections in aquaculture.

513 Socio-economic long-term impacts:

- 514 • change of public perception concerning marine/aquatic invertebrates leading towards a full
515 awareness of the socio-economic importance of marine/aquatic biodiversity. As a matter of fact,
516 degraded marine ecosystems provide fewer goods and services than healthy habitats via decreased
517 abundance of living species. As regards invertebrates, as reported below, they can be the source of
518 cellular systems which could be used for sustainable biotechnological production of new bioactive
519 molecules useful for human and animal health, and other applications (e.g., antifouling, enzymes for
520 biocatalysis, biopolymers, products of interest to pharmaceuticals, nutraceuticals and cosmetics) of
521 interest to biomedical and biotech industries. We cannot imagine a more powerful impact for a
522 project like this one;
- 523 • change of the social acceptability for the MISC importance in day to day life, not differently from
524 other bio- technologies;
- 525 • efficiently delivery of MISC results to potential stakeholders through specific meetings with SMEs
526 representatives;
- 527 • while still at early stages, MISC research is opening up a competitive niche of potentially lucrative
528 avenues for the development of protocols and technologies to isolate, cultivate and exploit MISCs.
529 Similarly, the MISC market is backed by biomedical research and bioprocessing;
- 530 • the availability of MISCs will also increase potential monetary benefits to society by adding novel
531 tools for scientific research, including mammalian stem cells biology. This reflects the objectives of
532 the European Strategy for Marine & Maritime Research and the last European Science Foundation
533 positional paper on marine biotechnology [2]. MISCs also represent one of the targeted topics in the
534 EC consortia ASSEMBLE [35] and EMBRC [36], aiming to promote marine laboratory
535 infrastructures;
- 536 • preparing young European researchers to launch careers in the MISC discipline and become the
537 new generation of MISC researchers in Europe.

538 **2.2. Measures to Maximize Impact**

539 **2.2.1. Plan for Involving the most Relevant Stakeholders**

540 At the start of the project, a dissemination plan will evaluate maximizing impacts using a: -who
541 (relevant end-users) -how (dissemination plan) -when approach.

542 The most relevant stakeholders that we identified are the following:

- 543 • SMEs, in particular: i) the antifouling paint sector that can take advantage from new natural
544 antifouling products preventing the growth of the bacterial film that triggers the adhesion of
545 encrusting organisms, without any concern for the environment and alternative to those currently in
546 use, which have profound effects on the biocoenoses once released in the environment [37]; ii) the
547 fine chemical sector, for a wide range of materials; iii) the nutraceuticals and cosmetic sector,
548 interested in new useful bioactive molecules; iv) the pharmaceutical and medical device sector,
549 where new antimicrobials are required to face the increasing number of bacterial strains resistant to
550 penicillin-based antibiotics; v) the human health sector, as new antimitotic compounds can be of

551 great help in the treatment of some kinds of cancer [23] and MISCs can provide new diagnostic and
552 treatment devices based on nanobioengineering [38, 39];
553 • the medical community, which can gain new knowledge on alternative molecular mechanisms of
554 aging, differentiation, tumor formation and regeneration operating in marine/aquatic invertebrates;
555 • the toxicologist, who can get new methods, tests and standards for safety evaluation of existing
556 and new substances;
557 • the broader scientific community studying stem cells, their role and differentiation pathways,
558 which can gain additional knowledge from the behavior of MISCs;
559 • the general public, who can gain benefits from the results of MISC research;
560 • the European networks interested in stem cells and MISCs, such as: i) EuroStemCell [33]; ii) the
561 Horizon 2020 research and innovation program aiming to help European citizens make sense of
562 stem cells; iii) ECVAM [33], European Commission reference Centre for the development and
563 validation of alternative testing methods to replace, reduce or refine the use of laboratory animals in
564 biomedical sciences; iv) ECACC, European Collection of Authenticated Cell Cultures, a supplier of
565 authenticated and quality controlled cell lines [32].

566 2.2.2. Dissemination and/or Exploitation Plan

567 Scientific community

568 The diffusion of the results of the project, via publication of joint research articles and presentation at
569 some of the most important international conferences in the field, together with organization of
570 courses and seminars will help us to improve the visibility and impact of our network on an
571 international scale. The detailed list of these dissemination activities includes:

- 572 • writing collaborative review articles on MISC research in peer-reviewed, high impact, open access
573 scientific journals;
- 574 • editing a scientific book focused on MISCs and/or regenerative biology;
- 575 • exploiting courses/workshops/meetings to disseminate the main outcomes of the Action among
576 scientists;
- 577 • promoting courses/teaching activities on MISCs in the European universities through the initiative
578 of the participants of this COST Action;
- 579 • promoting inter-university agreements aiming at an International PhD program on MISCs;
- 580 • introducing students, in a mentoring capacity, to research on MISCs for their degree thesis;
- 581 • creating new networks, within the MISC community, supporting applications for research funding
582 at national/international levels;
- 583 • participating in international conferences on stem cells. This will provide good opportunities to
584 share the results obtained within the proposed COST Action with a wider scientist network;
- 585 • proposing technical documents for standardization.

586 SMEs

- 587 • promoting transfer of knowledge, expertise and technical skills from the proposed COST Action to
588 the stakeholders as possible end-users through specific meetings/workshops;
- 589 • organizing specific workshops/meeting with industries to help the interaction with the
590 biotechnology world. Contact with some SMEs interested in areas reported above has already been
591 initiated and they will be invited to specific workshops, as indicated in section 3.1.2. Furthermore,
592 the aforementioned European networks will be contacted by the management committee of this
593 COST Action, and representatives will be invited to the meetings/workshops.

594 General public

595 It is clear to all of us that a pressing problem faced by EU countries in recent times is the
596 communication between scientists and the general public. The striking features of simple aquatic
597 organisms to which the general public is exposed during leisure activities at the seaside are good
598 ambassadors to communicate about the potential of European research to improve their daily life.
599 We want to emphasize that these planned activities are of special concern to us by:

- 600 • activating and maintaining active, even after the closure of this COST Action, an open website as a
601 preferential platform to share protocols, methods, etc. and to offer accessible knowledge to the
602 general public;
- 603 • working together with Innovation and Press offices at our Institutions to organize outreach and
604 public engagement activities for the general public, and to introduce the lay public to the research
605 performed by our network.

606 2.3. Potential for Innovation versus Risk Level

607 2.3.1. Potential for scientific, technological and/or socioeconomic innovation breakthroughs

608 Stem cell biology in vertebrates has a great deal to offer to society and industry. The ability to culture
609 vertebrate cells in the lab has supported tremendous breakthroughs in science over the years, from
610 the very foundations of cell biology to the cell therapy and tumor stem cell biology. It is evident from
611 the mammalian stem cell biology literature, that stem cells have been invaluable for treating a
612 number of intractable diseases, and that boundaries are continuously pushed and frequent
613 discoveries made. It is beyond dispute that innovative technologies in the mammalian stem cells
614 arena continue to proliferate, striving to advance the research. There are two main critical issues in
615 the clinical/commercial translation of stem cell intellectual property and products: (i)
616 entrepreneurial exploitation of breakthrough ideas and innovations, and (ii) regulatory market
617 approval. Thus, the commercial development of stem cells products and innovations reflects
618 potential high risks due to technological challenges, changing policies and markets, as well as
619 management changes, in this highly dynamic field. However, on the other hand, the benefits
620 incurred from a successful approach are tremendous. What is surprising about the recent stem cell
621 breakthrough in mammalian systems is that researchers make new discoveries that would otherwise
622 go uncharted if the research was not specifically focused on the stem cells biology. The same applies
623 for the MISC discipline, which answers the strategic breakthrough needs of various applied
624 biotechnology and healthcare issues, and provides additional innovative facets that are not found in
625 the mammalian stem cell discipline:

626 a) Comparative aspects. Comparative approaches on MISCs essentially consist of examining whole
627 genome structures, gene arrangement and rearrangement, stem cells lineages, stem cells properties
628 (such as stemness capabilities, structures, etc.) with the aim of delineating the evolution of gene
629 families and cell lineages, the cellular and molecular basis of adaptation (including the identification
630 of cells potentially involved in niche adaptation) as well as evolutionary relationships at various
631 taxonomic levels in the Tree of Life. The high *in vivo* plasticity of MISC shapes, structures, cell
632 replacements, proliferation processes and cell lineages encountered in different invertebrate taxa,
633 make a comparative approach highly valuable. In the mammalian stem cell arena, relatively few
634 comparative studies are available, and this lacuna severely constrains the potential value of many
635 predictions on stem cells origins, activities and fates.

636 b) Environmental approaches. They deal with the understanding of the functional significance of
637 cellular variation in MISCs - the basic unit of selection [31] - in natural biological entities. This
638 includes the use of various genotyping approaches to delineate the structure of inter- and
639 intraspecific biodiversity of MISCs, as well as the metagenomics approach of MISC, which treats
640 entire organisms (sometimes even populations) as carrying a single living entity. This has never
641 been addressed in the vertebrates in spite of various theoretical approaches [40].

642 c) Evolutionary perspectives. MISCs may also provide some understanding of evolutionary
643 relationships among different phyla and within-phylum groups. This is particularly valid for
644 organisms that possess MISC types with major evolutionary importance (such as stem cells in
645 colonial urochordates), either with respect to phyletic novelty or to structural cell lineages that can
646 only be investigated using an evolutionary approach. Looking to stem cell theories, we still have
647 only a poor understanding of stem cell origins and their importance in governing the dynamics of
648 stem cell populations over evolutionary time.

649 d) Changing of current dogma(s) such as disposable soma [41], irreversibility of aging [42],
650 germ/somatic cell barriers [43], as demonstrated by the capacity of whole body regeneration from
651 small fragments [26] or the ability to rejuvenate [44], easily found in marine/aquatic invertebrates.

652 3. Implementation

653 3.1. Description of the Work Plan

654 3.1.1. Description of Working Groups

655 We identified 4 working groups (WG), each involved in the analysis and the development of
656 different specific topics, as described below.

657 WG 1- Developing protocols for raising marine/aquatic invertebrate stem cells under *in vitro* 658 conditions

659 WG1 coordinates the activities of a series of tasks devoted to the development of common protocols,
660 problem solutions and tools (such as the development of resource services) in order to foster
661 integration of research institutions. It will focus on the tasks listed below. This will guide the
662 development of shared services and solutions not only within the research institutions but also into
663 the working environments of stakeholders and users to lay a solid foundation for long-term
664 cooperation.

665 Task 1.1 - new marine invertebrate models and access to marine resources

666 Task 1.2 - the problem of endosymbionts in establishment of pure or mixed cell cultures of MISC

667 Task 1.3 - methods for stem cell enrichment in culture

668 Task 1.4 - immortalization of marine/aquatic invertebrate stem cells

669 Task 1.5 - cryopreservation of marine/aquatic invertebrate stem cells

670 Deliverables:

671 • List of reference laboratories/institutions/marine stations for the supply of marine/aquatic
672 invertebrates

673 • Common protocols for MISC identification, isolation, rearing and storage

674 • Strategies to solve the problem of endosymbiont contamination that, up to now, made fruitless the
675 efforts of *in vitro* rearing of MISCs

676 WG 2- “omics” to characterize the MISC phenotypes

677 Technical and scientific capabilities to support the cooperation are coordinated by WG2:
678 molecular/biochemical profiling of novel model organisms needs data services for annotation,
679 analysis and archiving.

680 Task 2.1 - comparative functional genomics and transcriptomics of marine/aquatic invertebrate
681 tissues or derived MISCs

682 Task 2.2 - comparative proteomics of MISCs

683 Task 2.3 - differentiation molecular pathways of MISCs

684 Task 2.4 - development of strategies for “manipulating” stem cells (knockdown, CRISPR,
685 transgenesis, etc.)

686 Deliverables:

687 • Stem cell markers for aquatic invertebrate organisms

688 • Shared, trans-European open access database with molecular data of the organisms of interest,
689 with the possibility of continuous implementation by COST Action participants

690 WG 3- Blue technology: MISCs as model systems for the study of (see tasks):

691 Task 3.1 - evolutionary aspects of stem cell differentiation and development

692 Task 3.2 - cancer, aging and senescence phenomena

693 Task 3.3 - regeneration

694 Deliverables:

695 • Genes, signal transduction pathways, proteins involved in development, senescence, regeneration,
696 and suppression/induction of cancer

697 • Conserved detoxification pathways

698 • Evolutionary steps/passages in the evolution of development, senescence, regeneration

699 WG 4- Networking with stakeholders

700 The evaluation of the potential of MISCs to provide useful biomolecules is the focus of WG4.

701 Task 4.1- bioactive molecules. The technology developed in culture may be instrumental in solving
702 some practical tasks in marine biotechnology, including the generation of cell cultures producing
703 complex bioactive compounds with therapeutic potential. Stakeholders, some of which are already
704 part of the proposing network, will be contacted from the beginning of the COST project and invited
705 to participate in specific workshops in which the potential applications of MISCs will be discussed.

706 Deliverables:

707 • Bioactive molecules (antimicrobials, anticancer, opsonins, enzymes) of potential use in human
708 health, pharmaceuticals, nutraceuticals, cosmetics, antifouling paint formulation

709 The proposed timeline of the activities in the *MARISTEM* Action is shown in Table. 1.

Activity	Year 1		Year 2		Year 3		Year 4	
Initial Action meeting	+							
Management Committee (MC) meeting		+		+		+		+
Supervision Board (SB) meetings	+	+	+	+	+	+	+	+
Launch of Action website	+							
Workshops with stakeholders		+		+		+		
Courses on MISC			+		+		+	
Final meeting/conference								+
Summer/winter training school				+		+		+
WG1								
Task 1.1	+	+	+	+	+	+	+	+
Task 1.2		+	+	+	+			
Task 1.3			+	+	+	+	+	+
Task 1.4			+	+	+	+	+	+
Task 1.5		+	+	+	+	+	+	+
WG2								
Task 2.1	+	+	+	+	+	+	+	+
Task 2.2	+	+	+	+	+	+	+	+
Task 2.3		+	+	+	+	+	+	+
Task 2.4				+	+	+	+	+
WG3								
Task 3.1	+	+	+	+				
Task 3.2					+	+	+	+
Task 3.3			+	+	+	+	+	+
WG4								
Task 4.1		+	+	+	+	+	+	+

710 **Table 1.** Gantt diagram showing the planned COST activities to be applied in the *MARISTEM*
711 consortium.

712 3.1.2. Risk and Contingency Plans

713 Several risks to the success of the *MARISTEM* Action have been identified that could impact the
 714 outcomes. We also defined remediation activities that minimize or eliminate the risks.
 715 The main risks to the project are related to scientific tasks of WG1, as, up to now, none of the
 716 scientific approaches employed succeeded in getting cultures of immortalized MISCs. We contend
 717 that the failures in cultivating MISC were directly related to the major obstacles that are listed above,
 718 including the fragmentation of the scientific community working on MISC and the unavailable
 719 networking opportunities, the lack of European students and early career scientists with a thorough
 720 knowledge and expertise in the MISC discipline, the lack of connections with industries (technology
 721 transfer to potential end-users), the general lack of knowledge of MISC biology and the importance
 722 of knowing the intraspecific and interspecific communication of MISC cellular components for their
 723 survival. This is the reason why this project targets the weak points mentioned above. The envisaged
 724 positive aspects of the network - in terms of developing protocols, advancing the use of marine
 725 systems, understanding of the stem cell biology or the regeneration processes, the study of the
 726 effects of toxic components - far outweigh the current lack of a cultured stem cell system and the
 727 main risks of the project. The need for networking and coordination in this field are so evident that,
 728 even in the presence of negative results in establishing immortalized MISCs, the Action will
 729 undoubtedly generate new ideas and tools for research, and exert a positive influence on Action
 730 members, next-generation researchers and European researchers in the field of invertebrate stem
 731 cells.

732 3.2. Management Structures and Procedures

733 The Action will be carried out according to “Rules and Procedures for Implementing COST
 734 Actions”. This COST Action proposes a wide geographical network involving (at the initiating stage)
 735 26 institutions from 15 countries (14 COST countries and 1 NNC represented by 2 institutions).
 736 Among the COST countries, 4 are ITC (Inclusiveness Target Countries, represented by 5 institutions)
 737 and 1 is the cooperating state of Israel (Table 2). Contacts and collaboration with additional COST
 738 countries, as well as biotech industries, are underway. The overview of the structure of the
 739 *MARISTEM* Action, and the interplay among the 4 working groups (WGs) and the management
 740 committee (MC) are depicted in Fig. 2.


741

Country	ITC/non ITC/other	Number of Institutions from that country	Number of researchers from that country	Percentage of proposing network
Austria	non ITC	1	1	3.85%
Croatia	ITC	1	1	3.85%
France	non ITC	4	4	15.38%
Germany	non ITC	1	1	3.85%
Greece	non ITC	1	1	3.85%
Ireland	non ITC	1	1	3.85%
Israel	non ITC	2	2	7.69%
Italy	non ITC	5	5	19.23%
Norway	non ITC	1	1	3.85%
Poland	ITC	1	1	3.85%
Portugal	ITC	1	1	3.85%
Russian Federation	other	2	2	7.69%

Slovenia	non ITC	2	2	7.69%
Spain	non ITC	1	1	3.85%
United Kingdom	non ITC	2	2	7.69%

742 **Table 2.** Geographic distributions of proposers in the *MARISTEM* Action. ITC= Inclusiveness Target
743 Countries.

744



745

746

747 **Figure 2.** Pert Chart showing an overview of the structure of the *MARISTEM* Action and the
748 interplay relationships between the major components of the Action.

749 The management structure of the *MARISTEM* Action is as follows:

750 A Core Group (CG), composed of Action Chair, Vice chair, WG leaders and vice leaders, STSM
751 coordinator, meeting in person twice a year, will be the Consortium's highest decision-making body.
752 The Management Committee (MC) will coordinate the COST Action and will include senior
753 scientists from participating laboratories in each of the participating member states; it will be elected
754 at the outset of the Action. It will meet at least once a year. An international advisory board of 3-4
755 international scientists, experts in different areas of our program, will be invited to attend the annual
756 meetings in order to give critical feedback. Within the MC, a chair and a vice-chair will be elected.
757 The CG and the MC members will be elected at the kick-off meeting. The kick-off meeting will be
758 organized by the main proposer with the help of some secondary proposers.

759 The MC will:

- 760 - elect the Action Chair, Vice-Chair and task coordinators;
- 761 - nominate a coordinator for Short term scientific mission;
- 762 - nominate a coordinator for training schools;
- 763 - organize scientific workshops, training schools and the final meeting/conference;
- 764 - evaluate the progress of the scientific tasks from WG reports (every six months);
- 765 - evaluate the progress of other deliverable (e.g., workshops, schools);
- 766 - prepare the annual report;
- 767 - take care of the Action website;

- 768 - promote the contacts with other relevant EU networks;
769 - ensure that COST policies are followed, and specifically encourage active involvement of Early
770 Career researchers;

771 The CG will:

- 772 - overview the rationale for activities;
773 - ensure smooth operation of activities of the MC;
774 - decide conflicts between WG leaders and between participants;
775 - back the coordinator activities;

776 MC Chair: The MC chair will be the reference point for the Action, chair the annual
777 conference/meetings (together with the MC), be responsible for the preparation of all scientific
778 reports and the final report. The MC chair will be elected during the first meeting of the MC.

779 MC Vice-Chair: The MC Vice-Chair is also elected through the MC and should represent a different
780 research field than the MC Chair. The MC Vice Chair will primarily focus on practical issues
781 (organization of the Action) and represent the MC in relation to the “external world”.

782 WG leaders: Each WG will have two leaders from different countries/research backgrounds. Junior
783 researchers shall be actively promoted to take a lead in the WG. The WG leaders will coordinate the
784 WG networking and capacity building activities, stimulate Short Term Scientific meetings (STSMs)
785 and contacts with other WGs. The WG leaders are in charge of further subdividing the working
786 groups into sub-groups, coordinate the progress of these and prepare the WG output for the MC
787 reports.

788 **3.3. Network as a Whole**

789 Cellular (stem cells), genomic, proteomic and bioinformatic technologies are advancing rapidly and
790 it is often difficult for those involved in fundamental biological research aspects to keep up-to-date
791 and have access to the latest tools. These tools are often being developed by laboratories that are
792 restricted in their access to suitable and tractable models with which to fully exploit the full potential
793 of their powerful tools and their application to important healthcare problems. We believe that our
794 project will be unique in combining a network of EC laboratories that are at the forefront of using
795 organismal, cellular and genomic technologies with biologists studying the fundamental aspects
796 (such as stem cell biology, aging, regeneration and tumor formation), end users that are associated
797 with industries (five different sectors were outlined in section 2.2.1) and human well-being in the
798 EU, also tackling with the pressing environmental challenges our seas and oceans face right now.

799 This COST Action MARISTEM aims to create a novel research collaboration platform within a
800 scientific community that has, until now, been highly fragmented. It will lead to the consolidation of
801 research on MISCs at the European level in order to strengthen this emerging field in the academy
802 (e.g., by promoting the institution of university courses devoted to MISCs) and create synergy with
803 R&D institutions. Thus far, research on MISCs in Europe has been very limited, with scattered
804 expertise, and hampered by low funds and scarce attention by the scientific community. Bringing
805 together candidates from more than 20 European research institutions to work on common
806 objectives related to MISCs has the potential of producing a strong scientific impact in the field. In
807 this context, our project will be a comprehensive, integrated, multidisciplinary genomic and
808 proteomic approach to understand the basic biology of stem cells and regeneration. One of the main
809 aims will be, in the long term, to improve and enhance treatment of disease by utilizing homologous
810 gene networks and gene products to mobilize natural adult stem cell populations and to create
811 pluripotent cells. Others aims are to provide the scientific community with new biomolecules for
812 applied research.

813 The network will be the connecting avenue for all the people and institutions carrying out work on
814 aquatic organisms in Europe, with a critical mass of more than a hundred researchers, using various
815 model organisms, such as: Sponges, Cnidarians, Platyhelminthes, Mollusks, Echinoderms,
816 Crustaceans, Cephalochordates and Tunicates.

817 **Acknowledgments:** This study is supported by the European Cooperation in Science & Technology program
 818 (EU COST). Grant title: "Stem cells of marine/aquatic invertebrates: from basic research to innovative
 819 applications" (MARISTEM). The project idea developed as a direct outcome of a EuroMarine
 820 (European Marine Research Network) working group meeting, held in Padua on March 9-10, 2016.

821 **Author Contributions:** L.B. and B.R. conceived, initiated and designed the Action; L.B., B.R., P.M., I. D.-C.,
 822 A.-M.G. contributed to the writing of the text. L.B., B.R., K.B., A.B., S.C., M.C., I.D.-C., D.D., J.E., U.F., J.-M. G.,
 823 B.H., H.L., D.L., P.M., P.O., L.P., S.P., A.R., S.R., F.R., A.R., T.H.S., I.S., S.S., A.V.C. (the Management
 824 Committee) manage all activities of the MARISTEM project.

825 **Conflicts of Interest:** The authors declare no conflict of interest. The founding sponsors had no role in the
 826 design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, and in
 827 the decision to publish the results.

828 References

- 829 1. Ostend declaration. Available online:
 830 www.vliz.be/events/eurocean2010/attachments/Ostend%20Declaration.pdf (accessed on 16 January 2018).
- 831 2. Marine Board Position Paper 15, September 2010. Available online:
 832 www.marineboard.eu/science-strategy-publications (accessed on 16 January 2018).
- 833 3. Gordon, S. Phagocytosis: the legacy of Metchnikoff. *Cell* **2016**, *166*, 1065-1068, DOI:
 834 10.1016/j.cell.2016.08.017.
- 835 4. Duerden J.E. Aggregated colonies in madreporarian corals. *Am. Nat.* **1902**, *36*, 461-471.
- 836 5. Vacquier, V.D., Tegner, M.J., Epel, D. Protease released from sea urchin eggs at fertilization alters the
 837 vitelline layer and aids in preventing polyspermy. *Exp Cell Res* **1973**, *80*, 111-119. DOI:
 838 10.1016/0014-4827(73)90281-4.
- 839 6. Moy, G.W., Vacquier, V.D. Immunoperoxidase localization of bindin during the adhesion of sperm to sea
 840 urchin eggs. *Curr. Top. Dev. Biol.* **1979**, *13*, 31-44. DOI: 10.1016/S0070-2153(08)60688-2.
- 841 7. Terasaki, M., Sardet, C. Demonstration of calcium uptake and release by sea urchin egg cortical
 842 endoplasmic reticulum. *J. Cell Biol.* **1991**, *115*, 1031-1037.
- 843 8. Evans, T., Rosenthal, E.T., Youngblom, J., Distel, D., Hunt, T. Cyclin: a protein specified by maternal
 844 mRNA in sea urchin eggs that is destroyed at each cleavage division. *Cell* **1983**, *33*, 389-396. DOI:
 845 10.1016/0092-8674(83)90420-8.
- 846 9. Gehrke, A.R., Srivastavam M. Neoblasts and the evolution of whole-body regeneration. *Curr. Opin. Genet.*
 847 *Dev.* **2016**, *40*, 131-137. DOI: 10.1016/j.gde.2016.07.009.
- 848 10. Shimomura, O., Johnson, F.H., Saiga, Y. Extraction, purification and properties of aequorin, a
 849 bioluminescent protein from the luminous hydromedusan, *Aequorea*. *J. Cell. Comp. Physiol.* **1962**, *59*, 223-
 850 239. DOI: 10.1002/jcp.1030590302.
- 851 11. Rinkevich, Y., Matranga, V., Rinkevich, B.. Stem cells in aquatic invertebrates: common premises and
 852 emerging unique themes. In: *Stem cells in marine organisms*, Rinkevich, B., Matranga, V., Eds.; Springer:
 853 London, UK, **2009**; pp. 61-103, ISBN: 9789048127665.
- 854 12. Sköld, H.N., Obst, M., Sköld, M., Åkesson, B. Stem cells in asexual reproduction of marine invertebrates.
 855 2009. In: *Stem cells in marine organisms*, Rinkevich, B., Matranga, V., Eds.; Springer: London, UK, 2009; pp.
 856 105-137, ISBN: 9789048127665.
- 857 13. Gold, D.A., Jacobs, D.K. Stem cell dynamics in Cnidaria: are there unifying principles? *Dev. Genes Evol.*
 858 **2013**, *223*, 53-66. DOI: 10.1007/s00427-012-0429-1.
- 859 14. Knapp, D., Tanaka, E.M. Regeneration and reprogramming. *Curr. Opin. Genet. Dev.* **2012**, *22*, 485-493. DOI:
 860 10.1016/j.gde.2012.09.006.
- 861 15. Arenas-Mena, C. Indirect development, transdifferentiation and the macroregulatory evolution of
 862 metazoans. *Philos. Trans. R. Soc. Lond. B Biol. Sci.* **2010**, *365*, 653-669. DOI: 10.1098/rstb.2009.0253.
- 863 16. Directive 2010/63/eu of the European Parliament and of the Council. Available online:
 864 <http://eur-lex.europa.eu/legal-content/EN/TXT/PDF/?uri=CELEX:32010L0063&from=EN> (accessed on 16
 865 January 2018).
- 866 17. Blue Growth opportunities for marine and maritime sustainable growth. Available online:
 867 https://ec.europa.eu/maritimeaffairs/sites/maritimeaffairs/files/docs/body/com_2012_494_en.pdf
 868 (accessed on 16 January 2018).

- 869 18. Innovation in the blue economy. Available online:
870 <http://www.eubusiness.com/topics/fisheries/blue-economy> (accessed on 16 January 2018).
- 871 19. Innovation in the Blue Economy: realising the potential of our seas and oceans for jobs and growth.
872 Available online:
873 <http://eur-lex.europa.eu/legal-content/EN/TXT/PDF/?uri=COM:2014:254:REV1&from=EN> (accessed on 16
874 January 2018).
- 875 20. MARINE KNOWLEDGE 2020: marine data and observation for smart and sustainable growth. Available
876 online: <http://eur-lex.europa.eu/legal-content/EN/TXT/PDF/?uri=CELEX:52010DC0461&from=EN>
877 (accessed on 16 January 2018).
- 878 21. Adrian, T.E. Novel marine-derived anti-cancer agents. *Curr. Pharm. Des.* **2007**, *13*, 3417-3426. DOI:
879 10.2174/138161207782360500.
- 880 22. Gordaliza, M. Cytotoxic terpene quinones from marine sponges. *Mar. Drugs* **2010**, *8*, 2849-2870. DOI:
881 10.3390/md8122849.
- 882 23. D'Incalci, M., Galmarini, C.M. A review of trabectedin (ET-743): a unique mechanism of action. *Mol.*
883 *Cancer Ther.* **2010**, *9*, 2157-2163. DOI: 10.1158/1535-7163.MCT-10-0263.
- 884 24. Sunassee, S.N., Davies-Coleman, M.T. Cytotoxic and antioxidant marine prenylated quinones and
885 hydroquinones. *Nat. Prod. Rep.* **2012**, *29*, 513-535. DOI: 10.1039/c2np00086e.
- 886 25. Blunt, J.W., Copp, B.R., Keyzers, R.A., Munro, M.H., Prinsep, M.R. Marine natural products. *Nat. Prod. Rep.*
887 **2016**, *33*, 382-431. DOI: 10.1039/c5np00156k.
- 888 26. Rinkevich, B., Shlemberg, Z., Fishelson, L. Whole-body protochordate regeneration from totipotent blood
889 cells. *Proc. Natl. Acad. Sci. USA* **1995**, *92*, 7695-7699. DOI: 10.1073/pnas.92.17.7695
- 890 27. Smithers Rapra's Market Reports. Available online: <https://www.smithersrapra.com/market-reports>
891 (accessed on 16 January 2018).
- 892 28. HORIZON 2020. Available on line:
893 https://ec.europa.eu/programmes/horizon2020/sites/horizon2020/files/InfoKit_UK_240214_Final.pdf
894 (accessed on 16 January 2018).
- 895 29. Joint OECD/NNI International symposium on assessing the economic impact of Nanotechnology.
896 Available online: https://www.oecd.org/sti/nano/Washington%20Symposium%20Report_final.pdf.
- 897 30. Rinkevich, B., Matranga, V., Eds. Stem Cells in Marine Organisms. Springer: London, UK, **2009**, 369 pp,
898 ISBN: 9789048127665.
- 899 31. Weissman, I.L. Stem cells: units of development, units of regeneration, and units in evolution. *Cell* **2000**,
900 *100*, 157-168. DOI: 10.1016/S0092-8674(00)81692-X.
- 901 32. Public Health England, culture collections. Available online: <https://www.phe-culturecollections.org.uk>
902 (accessed on 16 January 2018).
- 903 33. Eurostemcell. Available online: <https://www.eurostemcell.org> (accessed on 16 January 2018).
- 904 34. EURL-ECVAM, European Union Reference Laboratory for alternatives to animal testing. Available online:
905 <https://eurl-ecvam.jrc.ec.europa.eu> (accessed on 16 January 2018).
- 906 35. ASSEMBLE, Association of European Marine Biological Laboratories. Available on line:
907 <http://www.assemblemarine.org> (accessed on 16 January 2018).
- 908 36. EMBRC, European Marine Biological Resource Centre. Available online: <http://www.embrc.eu> (accessed
909 on 16 January 2018).
- 910 37. Van Wezel, A., Van Vlaardingen, P. Environmental risk limits for antifouling substances.. *Aquat. Toxicol.*
911 **2004**, *66*: 427-444. DOI: 10.1016/j.aquatox.2003.11.003. DOI: 10.1016/j.aquatox.2003.11.003.
- 912 38. Kaur, S., Singhal, B. When nano meets stem: the impact of nanotechnology in stem cell biology *J. Biosci.*
913 *Bioeng.* **2012**, *113*, 1-4. DOI: 10.1016/j.jbiosc.2011.08.024.
- 914 39. Mooney, E., Dockery, P., Greiser, U., Murphy, M., Barron, V. Carbon nanotubes and mesenchymal stem
915 cells: biocompatibility, proliferation and differentiation. *Nano Lett.* **2008**, *8*, 2137-2143. DOI:
916 10.1021/nl073300o.
- 917 40. Rinkevich, B. A critical approach to the definition of Darwinian units of selection. *Biol. Bull.* **2000**, *199*,
918 231-240. DOI: 10.2307/1543179.
- 919 41. Kirkwood, T.B.L., Holliday, F.R.S. The evolution of ageing and longevity. *Proc. R. Soc. Lond. B* **1979**, *205*,
920 531-546. DOI: 10.1098/rspb.1979.0083.
- 921 42. Kirkwood, T., Melov, S. On the programmed/non-programmed nature of ageing within the life history.
922 *Curr. Biol.* **2011**, *21*, R701-707. DOI: 10.1016/j.cub.2011.07.020.

- 923 43. Ridley, M. *Evolution*, 3rd edition; Blackwell Publishing: Oxford, UK, 2004. ISBN: 1405103450.
- 924 44. Schmich, J., Kraus, Y., De Vito, D., Graziussi, D., Boero, F., Piraino, S. Induction of reverse development in
- 925 two marine Hydrozoans. *Int. J. Dev. Biol.* **2007**, *51*, 45-56. DOI: 10.1387/ijdb.062152js.
- 926